CIK 0000014272
- Large accelerated filer
BRISTOL MYERS SQUIBB CO
Sign in to watch- Ticker
- BMY
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 220790350
- Phone
- +1 609-252-4621
- Business address
- ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NJ, 08543
Securities
- BMY Bristol-Myers Squibb Company Common Stock NYSE
- CELG-RI Rights NYSE
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $677,826
- in 3 filings
Net −$677,826. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-07-30 | VESSEY RUPERT EVP, Research & Early Dev. | Option exercise · Option (right to buy) | −1,651 | 0 | ||
| 2021-07-30 | VESSEY RUPERT EVP, Research & Early Dev. | Option exercise · Option (right to buy) | −1,454 | 0 | ||
| 2021-07-30 | VESSEY RUPERT EVP, Research & Early Dev. | Option exercise · Option (right to buy) | −373 | 0 | ||
| 2021-07-30 | VESSEY RUPERT EVP, Research & Early Dev. | Option exercise · Option (right to buy) | −29,489 | 0 | ||
| 2021-07-30 | VESSEY RUPERT EVP, Research & Early Dev. | Option exercise · Option (right to buy) | −5,843 | 0 | ||
| 2021-07-30 | VESSEY RUPERT EVP, Research & Early Dev. | Option exercise · Option (right to buy) | −2,905 | 0 | ||
| 2021-07-30 | VESSEY RUPERT EVP, Research & Early Dev. | Option exercise · Option (right to buy) | −17,630 | 0 | ||
| 2021-07-30 | VESSEY RUPERT EVP, Research & Early Dev. | Option exercise · Option (right to buy) | −24,134 | 0 | ||
| 2021-07-30 | VESSEY RUPERT EVP, Research & Early Dev. | Option exercise · Option (right to buy) | −22,483 | 0 | ||
| 2021-07-30 | VESSEY RUPERT EVP, Research & Early Dev. | Option exercise · Option (right to buy) | −15,879 | 3,494 | ||
| 2021-07-30 | VESSEY RUPERT EVP, Research & Early Dev. | Option exercise · Option (right to buy) | −8,489 | 8,491 | ||
| 2021-07-30 | VESSEY RUPERT EVP, Research & Early Dev. | Option exercise · Option (right to buy) | −8,489 | 8,491 | ||
| 2021-07-30 | von Autenried Paul EVP, Chief Information Officer | Sale | −25,000 | $68.06 | $1.7M | 114,670.07 |
| 2021-07-30 | von Autenried Paul EVP, Chief Information Officer | Gift | −114,670.07 | 0 | ||
| 2021-07-30 | von Autenried Paul EVP, Chief Information Officer | Gift | +114,670.07 | 114,670.07 | ||
| 2021-07-01 | Hirawat Samit EVP,Chief Med.Offr.,Drug Dev. | Option exercise | +9,356 | 16,538 | ||
| 2021-07-01 | Hirawat Samit EVP,Chief Med.Offr.,Drug Dev. | Shares withheld for taxes | −4,786 | $66.56 | $319K | 11,752 |
| 2021-07-01 | Hirawat Samit EVP,Chief Med.Offr.,Drug Dev. | Option exercise · Restricted Stock Units | −9,356 | 18,713 | ||
| 2021-07-01 | Santiago Karen Murphy SVP & Controller | Option exercise | +1,069 | 15,045 | ||
| 2021-07-01 | Santiago Karen Murphy SVP & Controller | Shares withheld for taxes | −547 | $66.56 | $36K | 14,498 |
Page 70 of 73 · 1,445 trades